Finance

Lists
Why is 600812 up 10,05%?
Dive Deeper
600812:SHA
North China Pharmaceutical Co Ltd
CN¥6,57
+10,05%
(+0,60) 1D
15 Okt., 15:00:01 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600812...
Open
CN¥5,78
High
CN¥6,57
Low
CN¥5,71
Avg. vol.
50,81 m
Volume
334,29 m
Dividend
0,53%
Quarterly dividend
CN¥0,01
Ex-dividend date
11 Jun. 2026
P/E ratio
91,58
52-wk high
CN¥6,63
52-wk low
CN¥4,11
EPS
CN¥0,07
Shares outstanding
1,63 mjd
No. of employees
10 k
Open
CN¥5,78
High
CN¥6,57
Low
CN¥5,71
Avg. vol.
50,81 m
Volume
334,29 m
Dividend
0,53%
Quarterly dividend
CN¥0,01
Ex-dividend date
11 Jun. 2026
P/E ratio
91,58
52-wk high
CN¥6,63
52-wk low
CN¥4,11
EPS
CN¥0,07
Shares outstanding
1,63 mjd
No. of employees
10 k
News stories
From web sources and news partners
Profile
North China Pharmaceutical Group Corp., is a pharmaceutical manufacturer in China. NCPC was one of the key construction projects during China's First Five-Year Plan. After five years of construction since the foundation date in June 1953, the first successful pharmaceutical production, started in June 1958. Being one of the antibiotic producers both in technology and production scale at that time, NCPC created a history of commercial production of antibiotics in China. It has 45 years of development experience. NCPC has been taking the lead in the Chinese pharmaceutical industry in key economic indexes, ranked as one of the Top500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets of the company were valued at US$2 billion, with 18,500 employees. In 2002, NCPC claimed a domestic sales revenue of US$700 million and export sales of US$100 million. Wikipedia
About North China Pharmaceutical Co Ltd
CEO-
Employees9,97 k
Founded20 Des. 1992
Headquarters-
SectorPharmaceutical industry
Website-
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
2,21 mjd
1,76 mjd
2,15 mjd
2,07 mjd
Cost of goods sold
1,59 mjd
1,07 mjd
1,53 mjd
1,54 mjd
Cost of revenue
1,59 mjd
1,07 mjd
1,53 mjd
1,54 mjd
Research and development expenses
85,19 m
85,95 m
95,62 m
84,71 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
419,54 m
414,91 m
354,22 m
304,68 m
Operating expense
504,74 m
539,54 m
495,25 m
396,76 m
Total operating expenses
2,09 mjd
1,61 mjd
2,03 mjd
1,94 mjd
Operating income
116,01 m
149,57 m
128,11 m
125,58 m
Other non operating income
-299,86 k
-2,96 m
-10,58 m
6,02 m
EBT including unusual items
73,18 m
70,19 m
66,28 m
57,65 m
EBT excluding unusual items
45,54 m
84,31 m
61,80 m
58,08 m
Income tax expense
23,93 m
24,28 m
16,90 m
16,15 m
Effective tax rate
32,70%
34,59%
25,50%
28,02%
Other operating expenses
4,82 m
29,30 m
27,82 m
15,57 m
Net income
35,01 m
24,55 m
35,47 m
28,37 m
Net profit margin
1,58%
1,40%
1,65%
1,37%
Earnings per share
-
-
-
-
Interest and investment income
19,41 m
27,71 m
19,26 m
22,40 m
Interest expense
-85,85 m
-85,06 m
-74,99 m
-76,52 m
Net interest expenses
-66,43 m
-57,35 m
-55,73 m
-54,13 m
Depreciation and amortization charges
-
-
-
-
EBITDA
313,14 m
371,92 m
350,45 m
367,38 m
Gain or loss from assets sale
-9,85 k
-827,34 k
-
-217,80 k
AI content may include mistakes. Learn more
Google-programme